MY163236A - Polyethylene glycol-containing composition - Google Patents

Polyethylene glycol-containing composition

Info

Publication number
MY163236A
MY163236A MYPI2016000477A MYPI2016000477A MY163236A MY 163236 A MY163236 A MY 163236A MY PI2016000477 A MYPI2016000477 A MY PI2016000477A MY PI2016000477 A MYPI2016000477 A MY PI2016000477A MY 163236 A MY163236 A MY 163236A
Authority
MY
Malaysia
Prior art keywords
polyethylene glycol
containing composition
salt
formula
pharmaceutical composition
Prior art date
Application number
MYPI2016000477A
Other languages
English (en)
Inventor
Kenji Murai
Kazuhito Yamada
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of MY163236A publication Critical patent/MY163236A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
MYPI2016000477A 2013-09-20 2014-09-18 Polyethylene glycol-containing composition MY163236A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013195329 2013-09-20

Publications (1)

Publication Number Publication Date
MY163236A true MY163236A (en) 2017-08-30

Family

ID=52688941

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2016000477A MY163236A (en) 2013-09-20 2014-09-18 Polyethylene glycol-containing composition

Country Status (17)

Country Link
US (1) US20160228420A1 (cg-RX-API-DMAC7.html)
EP (1) EP3047850A4 (cg-RX-API-DMAC7.html)
JP (2) JP5856264B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160060656A (cg-RX-API-DMAC7.html)
CN (1) CN105555271A (cg-RX-API-DMAC7.html)
AU (1) AU2014322111A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016006153A2 (cg-RX-API-DMAC7.html)
CA (1) CA2924628A1 (cg-RX-API-DMAC7.html)
EA (1) EA201690621A1 (cg-RX-API-DMAC7.html)
HK (2) HK1221407A1 (cg-RX-API-DMAC7.html)
IL (1) IL244648A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016003566A (cg-RX-API-DMAC7.html)
MY (1) MY163236A (cg-RX-API-DMAC7.html)
PH (1) PH12016500461A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201602020QA (cg-RX-API-DMAC7.html)
TW (1) TW201518291A (cg-RX-API-DMAC7.html)
WO (1) WO2015041294A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3272360B1 (en) 2015-03-17 2022-11-23 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition comprising polypeptide
HK1246641A1 (zh) 2015-03-18 2018-09-14 参天制药株式会社 缓释性医药组合物
JP2017008047A (ja) * 2015-06-25 2017-01-12 参天製薬株式会社 注射剤
TWI755356B (zh) * 2015-07-01 2022-02-21 日商參天製藥股份有限公司 含檸檬酸酯之緩釋劑之用途
CN106902117A (zh) * 2015-12-23 2017-06-30 瑞阳(苏州)生物科技有限公司 一种预防或治疗脉络膜新生血管形成的药物
JP7018939B2 (ja) * 2016-09-26 2022-02-14 ルヤン （スーチョウ） バイオロジー サイエンス アンド テクノロジー カンパニー，リミテッド 眼疾患の治療のための組成物ならびに使用および調製方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA833692B (en) * 1982-05-28 1985-02-27 Beecham Group Plc Pharmaceutical formulations
JPS59101478A (ja) * 1982-11-29 1984-06-12 Sunstar Inc リグスチライドを安定に配合した水系組成物
JPH09110698A (ja) * 1995-10-19 1997-04-28 Taiho Yakuhin Kogyo Kk 経口用医薬組成物の製造法
EP1717229B1 (en) * 2004-02-17 2011-06-15 Santen Pharmaceutical Co., Ltd. Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein
JP4626353B2 (ja) * 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物
ES2368153T3 (es) * 2004-02-17 2011-11-14 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que presenta un grupo 4-piridilalquiltio que presenta amino (no) sustituido introducido en el mismo.
US20060153920A1 (en) * 2004-09-24 2006-07-13 Ketan Amin Lyophilized pharmaceutical compositions
WO2006086750A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
JP2009521493A (ja) 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
CN101687042A (zh) 2007-07-20 2010-03-31 爱尔康公司 用于递送作为受体酪氨酸激酶抑制剂(RTKi)的化合物至眼部的药物制剂
CA2706448C (en) * 2007-11-26 2016-08-16 Merial Limited Solvent systems for pour-on formulations for combating parasites
EP2403342A4 (en) 2009-03-03 2013-06-05 Alcon Res Ltd PHARMACEUTICAL COMPOSITION FOR IL-ADMINISTRATION OF TYROSINE KINASE RECEPTOR INHIBITING COMPOUNDS (RTKI)
MX2012000749A (es) * 2009-07-17 2012-01-27 Santen Pharma Co Ltd Bencensulfonato de 2-[[[2-[(hidroxiacetil) amino]-4-piridinil]meti l] tio]-n-[4-(trifluorometox)fenil]-3-piridincarboxamida, cristal del mismo, cristal polimorfo de este y metodos para la produccion de estos.
LT3158991T (lt) * 2010-01-28 2021-07-12 Eagle Pharmaceuticals, Inc. Bendamustino kompozicijos

Also Published As

Publication number Publication date
CN105555271A (zh) 2016-05-04
JP2016094442A (ja) 2016-05-26
BR112016006153A2 (pt) 2017-08-01
JP2015083565A (ja) 2015-04-30
JP5856264B2 (ja) 2016-02-09
EP3047850A1 (en) 2016-07-27
KR20160060656A (ko) 2016-05-30
HK1220632A1 (zh) 2017-05-12
SG11201602020QA (en) 2016-04-28
US20160228420A1 (en) 2016-08-11
CA2924628A1 (en) 2015-03-26
HK1221407A1 (en) 2017-06-02
TW201518291A (zh) 2015-05-16
AU2014322111A1 (en) 2016-04-07
WO2015041294A1 (ja) 2015-03-26
IL244648A0 (en) 2016-04-21
PH12016500461A1 (en) 2016-05-16
EP3047850A4 (en) 2017-05-10
MX2016003566A (es) 2016-06-02
EA201690621A1 (ru) 2016-07-29

Similar Documents

Publication Publication Date Title
JOP20180102B1 (ar) مركب صيدلاني
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
PH12016501151A1 (en) Nrf2 regulators
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12016500467A1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
SG11201804121RA (en) Novel biphenyl compound or salt thereof
MX2014000556A (es) Compuesto heterociclico fusionado y su uso para el control de plagas.
IN2015DN00598A (cg-RX-API-DMAC7.html)
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
PH12015500900B1 (en) A stabilized pemetrexed formulation
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
PH12016500461A1 (en) Polyethylene glycol-containing composition
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
MX2015008829A (es) Momelotinib deuterado.
MX2018001517A (es) Derivados sustituidos de guanidina.
IN2014DN11078A (cg-RX-API-DMAC7.html)
IN2014DN07996A (cg-RX-API-DMAC7.html)
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2015007309A (es) Derivado de hidantoina.
NZ717192A (en) Anti-inflammatory tripeptides
WO2014172363A3 (en) Combretastatin analogs